In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Acta Tropica
- Vol. 211, 105606
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 46 references indexed in Scilit:
- Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential TreatmentsPLOS Neglected Tropical Diseases, 2013
- A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery ProgrammesPLOS Neglected Tropical Diseases, 2012
- Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from TipifarnibAntimicrobial Agents and Chemotherapy, 2012
- Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In VivoPLOS ONE, 2011
- Adverse Events After the Use of Benznidazole in Infants and Children With Chagas DiseasePediatrics, 2011
- Structural basis for conservation in the CYP51 familyBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2011
- Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised ChildrenAntimicrobial Agents and Chemotherapy, 2010
- Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult PatientsAntimicrobial Agents and Chemotherapy, 2010
- Effects of Ravuconazole Treatment on Parasite Load and Immune Response in Dogs Experimentally Infected with Trypanosoma cruziAntimicrobial Agents and Chemotherapy, 2010
- Chagas disease: A Latin American health problem becoming a world health problemActa Tropica, 2010